In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

"I still put a lot of patients on adalimumab [Humira] because I think the TNF inhibitors are better for arthritis. That's not necessarily what the data say, but in the clinic, I feel like ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Discover the 7 warning signs of ulcerative colitis, plus breakthrough treatments and management strategies that can transform ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...